BSD Medical Ships BSD-2000 Hyperthermia System to University of California San Francisco Medical Center
July 31 2014 - 9:15AM
Business Wire
BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”)
announced today that the Company has shipped a BSD-2000
Hyperthermia System (BSD-2000) to the prestigious University of
California San Francisco Medical Center (UCSF Medical Center). UCSF
Medical Center is one of the nation's top 10 hospitals and is
recognized throughout the world for innovative patient care and
advanced technology (http://www.ucsfhealth.org/about/). UCSF
Medical Center is one of the premier providers of cancer care in
the world. The UCSF Medical Center Comprehensive Cancer Center
received the prestigious designation of "comprehensive" from the
National Cancer Institute and ranks sixth nationwide in National
Cancer Institute research grants. UCSF Medical Center has 7,000
employees and numerous locations.
“We are excited to have the BSD-2000 placed in this prestigious
cancer care facility," stated Brian Ferrand, BSD's Vice President
of Domestic Sales. UCSF is one of the world's leading medical
centers and has a long history of providing innovative therapies,
including hyperthermia. UCSF has previously purchased a BSD-500
Hyperthermia System from BSD. We are pleased they have decided to
also offer the innovative capabilities of the BSD-2000 to their
patients."
About the BSD-2000 Hyperthermia System
The BSD-2000 – developed and patented exclusively by BSD –
delivers localized therapeutic heating (hyperthermia) by applying
radiofrequency (RF) energy. The BSD-2000 creates a central focusing
of energy that can be electronically focused to target the shape,
size, and location of the tumor, thus providing dynamic control of
the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the
U.S. Food and Drug Administration (FDA) for use in conjunction with
radiation therapy for the treatment of cervical cancer patients who
are ineligible for chemotherapy. The BSD-2000 also has CE
(Conformité Européenne) Marking approval for the commercial sale in
Europe. CE marking approval is also recognized in many countries
outside of the EU.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy, which is delivered using focused radiofrequency (RF) and
microwave energy. BSD’s product lines include both hyperthermia and
ablation treatment systems. BSD’s hyperthermia cancer treatment
systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other
therapies such as radiation therapy. BSD’s microwave ablation
system has been developed as a stand-alone therapy to employ
precision-guided microwave energy to ablate (destroy) soft tissue.
The Company has developed extensive intellectual property, multiple
products in the market and established distribution in the United
States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States,
Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.
This press release may be deemed to contain forward-looking
statements, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Readers are
cautioned that these forward-looking statements are only
predictions and may differ materially from actual future events or
results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company
to produce the products to meet the demand, global economic
conditions and uncertainties in the geopolitical environment and
other risk factors set forth in the Company’s most recent reports
on Form 10-K and Form 10-Q. Any forward-looking statements in this
release are based on limited information currently available to the
Company, which is subject to change, and the Company will not
necessarily update the information.
BSD Medical CorporationTricia Ross, (310)
622-8226tross@finprofiles.com